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Introduction:  Surgical  treatment  for  chronic  thromboembolic  pulmonary  hypertension  (CTEPH)
is challenging.  Most  Portuguese  patients  with  CTEPH  have  been  referred  to  foreign  institutions
for treatment,  with  significant  social  and  economic  costs.  To  meet  this  emerging  need,  the  car-
diothoracic  surgery  department  of  Hospital  de  Santa  Marta,  Lisbon,  has  developed  a  dedicated
program  for  pulmonary  thromboendarterectomy  (PTE).  We  hereby  present  the  results  for  the
first 19  patients  treated.
Methods:  We  conducted  a  retrospective  analysis  of  all  19  patients  who  underwent  PTE  at
Hospital de  Santa  Marta  between  2008  and  April  2019.
Results:  Since  2008,  a  total  of  19  patients  have  undergone  PTE  in  our  department.  The  pro-
cedure was  performed  with  good  outcomes  in  both  survival  and  functional  recovery.  At  the
very beginning  of  the  series  two  patients  died  perioperatively,  before  all  the  team  underwent
formal training  at  the  Royal  Papworth  Hospital,  UK,  with  no  early  deaths  since.  Postoperative
complications  were  similar  to  other  published  series.  During  11  years  of  follow-up,  there  were
three late  deaths,  all  in  patients  with  residual  pulmonary  arterial  hypertension.  At  the  latest
follow-up (October  2019),  all  surviving  patients  showed  significant  functional  recovery,  all  in
NYHA class  I  or  II,  with  only  one  patient  on  vasodilator  therapy  with  sildenafil  (the  first  in  the
series, operated  in  2008).
Conclusions:  PTE  is  a  demanding  procedure,  in  which  outcomes  are  related  to  volume  and
accumulated  experience,  however  it  can  be  performed  safely  and  with  reproducible  results  by
a properly  prepared  dedicated  team  with  a  well-controlled  learning  curve.  More  patients  and
multidisciplinary  experience  will  be  needed  to  further  improve  and  streamline  results.sa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an
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Tromboendarterectomia  pulmonar  em  Portugal:  Experiência  inicial
Resumo
Introdução:  O  tratamento  cirúrgico  da  hipertensão  pulmonar  tromboembólica  crónica  (CTEPH)
é desafiante.  Até  ao  presente,  a  maioria  dos  doentes  portugueses  sofrendo  desta  patologia  têm
vindo a  ser  referidos  para  tratamento  em  instituições  estrangeiras,  com  importantes  custos
sociais e  económicos.  Para  responder  à  necessidade  de  desenvolvimento  de  um  tratamento
local de  qualidade  para  estes  doentes,  o  Serviço  de  Cirurgia  Cardiotorácica  do  Hospital  de
Santa Marta  (HSM)  tem  vindo  a  desenvolver  um  programa  dedicado  de  tromboendarterectomia
pulmonar  (PTE).  Apresentamos  os  resultados  com  os  primeiros  19  doentes.
Métodos:  Análise  retrospetiva  de  todos  os  19  doentes  submetidos  a  PTE  no  HSM  de  2008  a  abril
de 2019.
Resultados:  Desde  2008,  19  doentes  foram  tratados  no  Serviço  de  Cirurgia  Cardiotorácica  do
HSM, com  bons  resultados,  quer  a  nível  da  sobrevivência  quer  da  recuperação  funcional.
As complicações  pós-operatórias  são  semelhantes  às  descritas  na  literatura.  Ocorreram  duas
mortes perioperatórias  no  início  da  experiência,  antes  de  a  equipa  ter  feito  um  período  de
treino formal  no  Royal  Papworth  Hospital,  sem  mortalidade  precoce  desde  então.  Durante  os
11 anos  de  follow-up,  ocorreram  três  mortes  tardias,  em  doentes  com  algum  grau  de  hipertensão
pulmonar  residual.  À  data  do  último  seguimento  (outubro  de  2019),  os  doentes  vivos  apresen-
tavam recuperação  funcional  significativa,  encontrando-se  todos  em  classe  NYHA  I  ou  II.  Apenas
um (o  primeiro  desta  série,  operado  em  2008)  estava  sob  terapêutica  vasodilatadora  pulmonar
com sildenafil.
Conclusões:  A  PTE  é  um  procedimento  exigente,  em  que  os  resultados  estão  dependentes  de
volume de  casos  e  acumulação  de  experiência,  mas  que  pode  ser  realizada  com  segurança e
resultados reprodutíveis  por  uma  equipa  dedicada  com  uma  curva  de  aprendizagem  bem  con-
trolada. Mais  doentes  e  experiência  multidisciplinar  serão  necessários  para  melhorar  e  otimizar
os resultados.
© 2020  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este é um












































hronic  thromboembolic  pulmonary  hypertension  (CTEPH)
s  a  form  of  pulmonary  arterial  hypertension  (PAH)
esulting  from  the  fibrotic  transformation  of  pulmonary
rtery  clots  causing  chronic  obstruction  of  the  pul-
onary  arteries,  leading  to  vascular  remodeling  in  the
icrovasculature.  Consequently,  pulmonary  arterial  pres-
ure  and  vascular  resistance  increase,  leading  inexorably  to
ight  heart  failure,  functional  impairment  and  premature
eath.
Not  all  patients  with  CTEPH  report  a  history  of  acute
ulmonary  embolism  (PE);  the  incidence  of  CTEPH  after  PE
s  around  1.5%  and  registry  data  indicate  a  prevalence  of
-30  per  million  in  the  general  population.1 However,  most
TEPH  patients  present  with  a  previous  PE.  The  Interna-
ional  CTEPH  Registry  reports  a  previous  acute  PE  event  in
4.8%  of  CTEPH  patients,  and  the  cumulative  incidence  is
eported  to  be  0.1-9.1%  within  two  years  of  any  symptomatic
ulmonary  embolic  event.
Although  the  exact  prevalence  and  annual  incidence  of
TEPH  are  unknown,  some  data  suggest  that  the  condition
ay  occur  in  approximately  five  per  million  population  per
ear.  Its  prevalence  in  European  countries  is  3.2  cases  per
illion  per  year,  and  is  0.9  cases  per  million  in  Spain,2 which,




eans  that  a  reasonable  estimate  for  Portugal  would  be  nine
ew  cases  yearly.
The  true  incidence  and  prevalence  of  CTEPH  in  the  Por-
uguese  population  are  unknown,  although  according  to
ouveia  et  al.3 the  estimated  incidence  of  acute  pulmonary
mbolism  in  Portugal  in  2013  was  35  per  100  000  population.
n  a  nationwide  study  by  Baptista  et  al.,4 after  excluding
atients  in  World  Health  Organization  (WHO)  PAH  groups  2,  3
nd  5,  CTEPH  patients  comprised  41.8%  of  all  those  with  PAH.
his  study,  based  on  a  small  number  of  patients  followed  at
edicated  PAH  centers,  remains  the  sole  nationwide  data
vailable  for  CTEPH.
Predisposing  factors  such  as  thrombophilic  disorders,
upus  anticoagulant  and  antiphospholipid  antibody  syn-
romes,  protein  S  and  C  deficiency,  activated  protein  C
esistance  including  factor  V  Leiden  mutation,  thrombotic
ene  mutations,  antithrombin  III  deficiency  and  elevated
actor  VIII  have  been  reported  in  31.9%  of  patients  and  pre-
ious  splenectomy  in  3.4%.2
iagnosis and assessment of operability diagnosis  of  CTEPH  is  based  on  findings  obtained  after  at
east  three  months  of  effective  anticoagulation,  in  order  to
ifferentiate  this  condition  from  subacute  forms  of  PE.2
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Table  1  Clinical  characteristics  of  the  study  population  at
diagnosis  (n=19).
Demographics
Age,  years  54.8±14.8
Male  gender 36.8  (7)
BMI, kg/m2 26.8±5.1
Genetics  (confirmed)  21  (4)
Preoperative
Creatinine,  mg/dl  0.76±0.23
Systemic  hypertension  68.42  (13)
Diabetes  15.8  (3)
Smoking  history  26.3  (5)
COPD 15.8  (3)
Previous  MI  5  (1)
Previous  acute  event  31.6  (7)
Clinical
NYHA I/II  5  (1)
NYHA≥III  94.7  (18)
Use of  pulmonary  vasodilators  21  (4)
Supplementary  O2 36.8  (7)
Echocardiography
PASP, mmHg 100.5±14.84
TAPSE,  mm 14.5±0.7
TR  grade>III  47.4  (9)
Hemodynamics
mPAP,  mmHg  45.6±13.4
PASP,  mmHg  81.4±24.3
PVR,  WU  22.8±6.8
PVR,  dyn.s.cm5 1821.6±575.1
PVR>12.5  WU/1000  dyn.s.cm5 42  (8)
CI, l/min/m2 2.02±0.68
Values are percentage (n) or mean ± standard deviation.
One patient had a previous myocardial infarction treated with
percutaneous coronary intervention of the left anterior descend-
ing artery.
BMI: body mass index; CI: cardiac index; COPD: chronic obstruc-
tive pulmonary disease; MI: myocardial infarction; mPAP: mean
pulmonary artery pressure; NYHA: New York Heart Association
class; PASP: pulmonary artery systolic pressure; PVR: pulmonary









Pulmonary  thromboendarterectomy  in  Portugal  
The  clinical  criteria  for  diagnosis  according  to  the  2015
European  Society  of  Cardiology/European  Respiratory  Soci-
ety  (ESC/ERS)  guidelines  were  mean  pulmonary  artery
pressure  (mPAP)  ≥25  mmHg  (revised  in  2018  to  ≥20  mmHg),
pulmonary  artery  wedge  pressure  ≤15  mmHg,  and  spe-
cific  diagnostic  signs  for  CTEPH  on  imaging  studies.  These
include  mismatched  perfusion  defects  on  lung  scan  (a  normal
V/Q  scan  effectively  excludes  CTEPH  with  a  sensitivity  of
90-100%  and  specificity  of  94-100%),  and  ring-like  stenoses,
webs/slits  and  chronic  total  occlusions  (pouch  lesions  or
tapered  lesions).2 Imaging  studies  --  multidetector  com-
puted  tomography  (CT)  angiography,  magnetic  resonance
imaging  (MRI),  or  conventional  pulmonary  cineangiography
-- are  essential  for  diagnosis  and  lesion  characterization  and
to  guide  surgical  intervention.  At  least  two  imaging  methods
are  recommended;  elective  pulmonary  cineangiography  can
be  replaced  by  MRI  or  CT  scan.
In  addition  to  imaging  studies,  patients  should  undergo
right  heart  catheterization,  an  echocardiogram,  and  car-
diorespiratory  functional  testing  such  as  the  6-min  walk  test
or  treadmill  exercise  testing.6,7
Acceptance criteria
Pulmonary  thromboendarterectomy  (PTE)  is  the  treatment
of  choice  for  patients  with  CTEPH,  both  for  symptomatic
relief  and  for  improvement  or  normalization  of  pulmonary
hemodynamics.
There  is  general  agreement  in  the  literature  that  PTE
should  be  offered  to  every  operable  patient  with  CTEPH  if
the  risk  is  acceptable,  since  this  provides  survival  benefit.
According  to  the  guidelines,  operability  is  determined  by
multiple  factors  that  are  not  easily  standardized.  Certain
features  such  as  the  degree  of  pulmonary  vascular  resistance
(PVR)  and  location  of  thrombotic  lesions  are  strongly  related
to  outcomes.8,9
To  be  considered  operable,  a  patient  must  have  sufficient
surgically  accessible  thromboembolic  material,  and  more
importantly,  a  good  correlation  between  the  extent  of  dis-
ease  and  the  degree  of  PVR.  Extensive  secondary  peripheral
vasculopathy  should  be  excluded.1,6,9
Patients  of  advanced  age,  frail  or  in  poor  general  condi-
tion,  or  with  serious  comorbidities,  are  generally  deemed
to  be  inoperable  due  to  their  overall  surgical  risk.  Operabil-
ity  is  best  established  based  on  a  case-by-case  analysis,  and
borderline  cases  will  certainly  need  a  second  opinion.
Although  registry  data  suggest  that  in  the  past  more  than
one  third  of  patients  diagnosed  with  CTEPH  did  not  proceed
to  PTE  surgery,  PTE  should  be  offered  to  the  majority  of
patients.1,6,9,10
Although  PTE  is  the  treatment  of  choice  for  CTEPH,  it  is
still  not  widely  available  to  the  Portuguese  population,  with
only  a  small  number  of  patients  being  referred  to  interna-
tional  centers,  at  considerable  personal  and  societal  cost.11
Since  2008,  the  cardiothoracic  surgery  department  of
Hospital  de  Santa  Marta  in  Lisbon  has  been  operating  a
PTE  program,  providing  surgical  treatment  to  Portuguese
patients  with  CTEPH.  The  department  provides  the  full
range  of  services  needed  to  perform  and  support  this  type
of  surgery,  including  cardiothoracic  surgery,  structural  car-




excursion; TR: tricuspid regurgitation; WU: Wood units.
embrane  oxygenation  (ECMO)  and  lung  transplantation
rograms.  We  hereby  present  the  initial  experience  with  this
ngoing  program.
ethods
e  retrospectively  analyzed  data  from  all  patients  who
nderwent  PTE  at  our  center.  These  patients  were  referred
y  our  local  PAH  team,  as  well  as  by  other  expert  PAH  teams
n  the  country.
All  patients  were  diagnosed  and  assessed  according  to
he  ESC/ERS  guidelines,  at  least  two  imaging  tests  (CT  scan
nd  pulmonary  angiography)  being  required  to  determine
he  diagnosis  and  establish  operability.
Baseline  patient  characteristics  are  described  in  Table  1.
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Figure  3  Surgical  specimen  from  patient  3.  Note  the  large
quantity  of  clot  casts  and  webs  removed,  which,  together  with
the reduction  in  pulmonary  artery  pressure  confirmed  immedi-
ately  after  surgery,  led  us  to  expect  a  good  outcome.  However,
the patient  did  not  survive.
Table  2  Surgical  times.
Duration  of  surgery,  min  256.9±58.0
Bypass  time,  min  185.5±66.7
Cross-clamp  time,  min  48.3±11.9
Cumulative  circulatory  arrest  time






















Figure  2  Surgical  specimen  of  predominant  webs.
urgical protocol
ll  patients  were  operated  electively,  by  the  same  surgical
eam,  following  the  same  standard  perioperative  protocol.
All  procedures  were  performed  with  aortic  and  double
enous  cannulation,  right  superior  pulmonary  vein  and  main
ulmonary  artery  venting,  single-shot  cold  blood  cardiople-
ia  and  standard  circulatory  arrest  periods  of  20  min  at  18 ◦C
asopharyngeal  temperature.  If  circulatory  arrest  periods
onger  than  20  min  were  needed,  10-min  reperfusion  periods
ere  mandatory  between  arrest  periods.
Standard  modified  ultrafiltration  and  cerebral  protection
easures  were  routinely  used.
The  central  pulmonary  arteries  were  mobilized  up  to  the
ilum,  taking  care  not  to  open  the  pleurae,  then,  under  peri-
ds  of  complete  hypothermic  circulatory  arrest  and  total
xsanguination,  pulmonary  endarterectomies  were  carried
ut  sequentially,  first  on  the  right,  then  on  the  left  side.
The  critical  step  is  the  development  of  the  correct
issection  plane,  followed  by  meticulous  circumferential
issection,  extending  distally  to  the  segmental  and  subseg-
ental  branches.  This  enables  the  removal  of  full  casts  and
ebs,  leading  to  effective  relief  of  obstruction  (Figures  1-3).
After  direct  closure  of  the  pulmonary  arteriotomies
ith  5-0  nylon  sutures,  patients  are  fully  rewarmed  and
eaned  off  cardiopulmonary  bypass.  Inotropic  support  is
sed  according  to  our  protocol,  typically  in  low  to  moderate
osages.  Meticulous  hemostasis  is  achieved.
n
(
Values are mean ± standard deviation.
Only  the  first  patient  (in  2008)  underwent  tricuspid  annu-
oplasty;  none  of  the  other  patients  had  their  functional
ricuspid  regurgitation  addressed  at  surgery,  since  recovery
s  expected  after  removing  right  ventricular  afterload,  as
tated  in  the  literature.12
Operative  specimens  are  systematically  documented
Figures  1-3).
Mean  surgical  times  are  displayed  in  Table  2  and  some
perative  specimens  are  shown  in  Figures  1  and  2.
ostoperative management
ostoperative  care  is  conducted  according  to  published
rotocols,  paying  particular  attention  to  prevention  and
anagement  of  reperfusion  edema.
Inotropic  support  use  was  determined  by  hemodynamic
nd  echocardiographic  monitoring.  Low-dose  dobutamine
nd  noradrenaline  are  most  frequently  used,  other  inotropes
r  vasodilators  being  added  according  to  clinical  circum-
tances.
Negative  fluid  balance  (by  fluid  restriction  and  intra-
enous  furosemide)  is  crucial  in  the  management  of  these
atients,  as  is  early  adequate  anticoagulation.  Anticoag-
lant  therapy  consists  of  low  molecular  weight  heparin
1  mg/kg,  twice  daily),  started  as  early  as  possible  (ideally
n  the  first  24  hours  if  surgical  bleeding  is  <50  cc/h),  and
witched  over  to  oral  anticoagulation  with  vitamin  K  antago-
ists,  until  therapeutic  international  normalized  ratio  levels
around  3)  are  achieved.
Postoperative  data  are  summarized  in  Table  3.
Pulmonary  thromboendarterectomy  in  Portugal  
Table  3  Postoperative  data.
Hospital  stay
ICU  stay,  days  9.2±8.5
Total  stay,  days  21.5±12.9
Complications
Pulmonary  steal  31.6  (n=6)
Reperfusion  edema 5  (n=1)
ARDS 5  (n=1)
Renal dysfunction 5.26  (n=1)
Inotropes>24  h  52  (n=10)
Bleeding>10  mg/kg/24
h and/or  transfusion
57.9  (n=10)
Discharge
Home  73.68  (n=14)
Other  hospital  26.31  (n=5;  three
patients  later  discharged






Late  mortality  15.78  (n=3)b
a At the beginning of the study period.
b Over the 11 years of the study period.
Values are percentage (n) or mean ± standard deviation.













































The  mean  age  of  the  patients  was  54.8±14.8  years.  They
were  predominantly  female  (63.2%),  had  a  history  of  a  pre-
vious  acute  event  in  31.6%  of  cases,  and  in  21%  of  cases  there
were  confirmed  genetic  procoagulant  conditions.
As  expected,  most  patients  (91.7%,  n=14)  presented  with
significant  clinical  and  functional  impairment,  in  New  York
Heart  Association  (NYHA)  class  III  or  IV.  Oxygen  supplementa-
tion  was  needed  in  36.8%  and  21%  were  on  chronic  pulmonary
vasodilator  therapy.
Echocardiography  showed  severe  pulmonary  hyperten-
sion  and  right  ventricular  dysfunction  in  all  patients,  47.4%
of  patients  presenting  with  severe  (grade  III  or  IV)  tricuspid
regurgitation.  Hemodynamic  data  confirmed  the  echocar-
diographic  findings,  with  a  significant  proportion  of  patients
(42%)  presenting  with  severely  elevated  PVR  (>12.5  Wood
units/1000  dyn.s.cm5).  Cardiac  output  was  uniformly  low.
Baseline  patient  characteristics  are  described  in  Table  1.
Operative  data
Given  the  nature  of  this  surgical  technique,  surgical  times
tend  to  be  long,  particularly  due  to  the  cooling  and  rewarm-
ing  phases.  Cross-clamp  and  circulatory  arrest  times  were
within  the  recommended  limits.





Operative  data  are  summarized  in  Table  2  and  some  oper-
tive  specimens  are  shown  in  Figures  1  and  2.
ostoperative  course  and  complications
ostoperative  course  was  frequently  prolonged,  with  a  mean
ntensive  care  unit  stay  of  9.2±8.5  days  and  total  length  of
tay  of  21.5±12.9  days.
Pulmonary  complications  were  the  most  common,  occur-
ing  in  eight  patients.  Of  these,  six  (31.6%)  presented  with
ome  form  of  pulmonary  steal  syndrome  with  persistent
ypoxemia,  requiring  prolonged  ventilation  or  supplemen-
ary  oxygen  postoperatively.  One  patient  presented  with
rank  pulmonary  reperfusion  edema  and  one  patient  had
ull-blown  acute  respiratory  distress  syndrome.  Renal  dys-
unction  occurred  in  one  patient,  without  need  for  renal
eplacement  therapy.
Central  nervous  system  complications  were  rare  and  if
resent  were  mild,  presenting  as  mood  changes  and/or  agi-
ation.
Need  for  inotropes  for  more  than  48  h  was  frequent,
lbeit  at  low  dosages.
Transfusion  was  frequent,  due  to  a  relatively  lib-
ral  transfusion  strategy  (transfusion  threshold  ≤8  g/dl
emoglobin),  but  no  patients  needed  reoperation  for  bleed-
ng.
ECMO  support  was  not  needed  postoperatively.
Most  patients  (73.68%,  n=14)  were  discharged  home,  with
 small  number  (26.31%,  n=5)  being  transferred  to  the  refer-
ing  hospitals  due  to  delayed  recovery.  Of  these,  three
atients  were  later  discharged  home  having  made  an  ade-
uate  recovery  and  two  died  at  the  referring  hospital.
Due  to  the  small  sample  number,  these  delayed  recover-
es  weighed  heavily  in  the  length  of  stay  numbers.
ollow-up
omplete  follow-up  was  achieved  in  all  patients.
As  to  long-term  outcomes,  by  October  2019,  14  patients
ere  alive  and  all  had  experienced  significant  functional
ecovery,  being  in  NYHA  class  I  or  II,  and  there  had  been
onsistent  improvement  in  hemodynamic  parameters  (con-
rmed  in  some  patients  by  right  heart  recatheterization).
nly  one  patient  is  on  vasodilator  therapy,  with  sildenafil
the  first  in  the  series,  operated  in  2008).  Although  on
ildenafil,  this  patient  is  currently  in  NYHA  class  II.  Present
umbers  are  still  too  small  for  any  meaningful  survival  anal-
sis.
ortality
wo  patients  died  perioperatively,  in  2011  and  2012,  before
ll  of  the  team  underwent  formal  training  in  the  experienced
enter  at  the  Royal  Papworth  Hospital,  UK.  One  patient  died
rom  intraoperative  pulmonary  artery  rupture  and  the  other
rom  fulminant  hemoptysis  on  the  sixth  postoperative  day.
hese  two  early  deaths  were  probably  related  to  the  fact
hat  they  were  operated  early  in  our  learning  curve.
At  11  years  of  follow-up,  three  late  deaths  had  occurred,
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CAD: coronary artery disease; CI: cardiac index; COPD: chronic obstructive pulmonary disease; D: cause of death; Dis: time of discharge; Dist to: discharged to; LAD: left anterior descending
artery; LIMA: left internal mammary artery; LVEF: left ventricular ejection fraction; mPAP: mean pulmonary artery pressure; N: no; O2: supplementary oxygen; PASP: pulmonary artery
systolic pressure; PCI: percutaneous coronary intervention; PE: pulmonary embolism; PO: postoperative day; PTE: pulmonary thromboendarterectomy; PVR: pulmonary vascular resistance;







































Pulmonary  thromboendarterectomy  in  Portugal  
hypertension.  One  patient,  with  ischemic  cardiomyopathy
and  left  ventricular  dysfunction  (left  ventricular  ejection
fraction  40%)  died  two  months  postoperatively,  from  docu-
mented  H1N1  infection  followed  by  sepsis  and  renal  failure.
The  other  two  patients  were  considered  high  risk,  with
severe  functional  limitation  and  extensive  disease.  Despite
relief  of  pulmonary  arterial  obstruction,  one  of  these
patients  died  three  months  postoperatively  from  respiratory
infection  and  failure.  The  third  patient,  with  pre-existing
severe  lung  parenchymal  disease,  suffered  rethrombosis  of
the  right  pulmonary  artery  despite  appropriate  anticoagu-
lation,  and  died  from  pneumonia  and  respiratory  failure  on
postoperative  day  36  in  the  referral  hospital.
As  suggested  in  the  literature,  late  deaths  may  occur  due
to  unrelated  causes  in  up  to  49%  of  patients,  particularly
those  with  some  residual  pulmonary  hypertension  and  ele-
vated  PVR  (≥425  dyn.s.cm5).  This  cutoff  has  been  shown  to
correlate  with  worse  survival10 and  is  in  line  with  the  late
mortality  in  our  series.  In  Table  4  and  Figure  3,  we  review
our  late  mortality  cases  in  detail.
Discussion
This  paper  presents  data  on  the  initial  experience  with  PTE
performed  at  a  single  center  in  Portugal.
Results  achieved  so  far  by  our  center  show  acceptable
survival  and  complication  rates,  well  within  the  expected
range,  given  the  level  of  our  present  experience.
The  importance  of  a  comprehensive  multidisciplinary
approach  cannot  be  overestimated.  Such  an  approach  has
undoubtedly  helped  to  smooth  the  effects  of  the  learning
curve,  keeping  patients  safe  and  within  expected  functional
outcomes.
As  for  any  complex  surgical  procedure,  PTE  requires  high
surgical  volumes  and  accumulation  of  experience  in  order
to  achieve  reproducible  results  and  clinical  excellence,  as
stated  in  the  updated  recommendations  from  the  2018
Cologne  Consensus  Conference.13 In-hospital  fatalities  cor-
relate  inversely  with  the  number  of  cases  performed  yearly.
Specialized  centers  (those  performing  over  50  PTE  proce-
dures/year)  show  case  fatality  rates  of  ≤3.5%.  For  centers
performing  between  11  and  50  PTE  procedures/year,  mortal-
ity  averages  4.7%,  and  for  centers  that  perform  fewer  than
11  PTE/year  it  averages  7.4%.  Our  center  is  presently  in  the
latter  group.
The  recommended  minimum  number  of  PTE  procedures
to  be  performed  annually  is  20;  an  expert  center  should
perform  at  least  20  PTE  operations  per  year  with  less  than
10%  mortality.6 Also  in  line  with  these  recommendations,  an
experienced  surgeon  is  defined  as  one  who  performed  over
20  PTEs  in  the  year  they  were  first  assessed,  and  cumula-
tively  over  40  procedures  in  the  previous  three  years.6,10
For  Portugal,  a  yearly  case  load  of  20  PTEs  could  easily
be  achieved,  allowing  for  reproducible  results  and  making
Hospital  de  Santa  Marta  an  expert  center.
We  believe  that  by  increasing  referrals,  we  are  now  build-
ing  up  a  solid  experience  with  PTE.  Nevertheless,  we  might
still  occasionally  have  to  refer  more  complex  and  challeng-
ing  cases  for  surgery  abroad,  particularly  those  with  severe





n  order  to  provide  patients  with  the  best  possible  treat-
ent.
The  recognition  of  our  center  as  a  national  reference
enter  for  adult  PAH  and  PTE,  following  a  nationwide  open
ontest,  would  enable  us,  in  close  collaboration  with  every
AH  unit  in  Portugal,  to  build  up  a robust  national  PTE  center.
nly  by  increasing  the  PTE  case  load  and  closely  monitoring
ur  results  and  auditing  our  data  in  a  transparent  way  will
his  aim  be  achieved.
onclusions
his  is  a  brief  report  of  an  initial  series  of  PTE  procedures,
erformed  at  a  single  center.  The  numbers  are  still  small,  but
esults  are  encouraging,  reflecting  a  rapidly  rising  learning
urve,  without  undue  complications  or  mortality.
Complication  rates  are  consistent  with  those  published
n  the  literature,  including  transient  pulmonary  dysfunction,
hich  occurred  in  less  than  half  of  cases.
Long-term  outcomes  showed  a consistent  improvement  in
YHA  class  and  hemodynamic  parameters,  with  all  patients
n  NYHA  class  I or  II.
Late  mortality  occurred  in  a few  patients,  due  to  a  combi-
ation  of  pre-existing  clinical  severity  and  residual,  though
oderate,  pulmonary  hypertension.
Present  numbers  are  still  too  small  for  any  meaningful
ong-term  survival  analysis.
We  conclude  that,  with  a  multidisciplinary  team,  it  is  pos-
ible  to  start  a local  program  for  PTE  and  to  manage  the
earning  curve,  with  reproducible  results.
Undoubtedly,  more  patients  will  be  needed  to  further
mprove  results,  but  we  feel  our  initial  findings  are  encour-
ging.
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